Koh Sze Kiat/E+ via Getty ImagesOn January 8, Ardelyx (NASDAQ:ARDX) provided a surprise business update. The stock surged that day to $8.18 (+33%) after management proclaimed that lead product IBSRELA (tenapanor for irritable bowel syndrome with constipation [IBS-C]) would corner 10% market share on its way to blockbuster status on US net product sales alone. Originally scheduled for February 29, the Q4 2023 financial report was bumped up to February 22, normally a good sign, but my previous coverage wa ...

In the stock market, identifying potential millionaire-making stocks can lead to a situation like finding needles in a haystack. However, under ongoing volatility, three companies have emerged as prime contenders for high returns. Beyond names, these companies hold a strategic edge, rapid growth capabilities, and solid market strategies.The first one stands at the edge of AI-based solutions, leveraging strategic partnerships and an operational edge to propel its valuation. Meanwhile, the second one defies m ...

Start Time: 16:30 January 1, 0000 5:21 PM ET Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Conference Call February 22, 2024, 16:30 PM ET Company Participants Mike Raab - President and CEO Justin Renz - Chief Financial and Operations Officer Laura Williams - CMO Susan Rodriguez - Chief Commercial Officer Caitlin Lowie - VP of Corporate Communications and IR Conference Call Participants Dennis Ding - Jefferies Chris Raymond - Piper Sandler Laura Chico - Wedbush Louise Chen - Cantor Fitzgerald Yigal Nochomovit ...

Ardelyx (ARDX) reported $34.36 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 22.2%. EPS of -$0.12 for the same period compares to $0.06 a year ago.The reported revenue represents a surprise of -0.18% over the Zacks Consensus Estimate of $34.42 million. With the consensus EPS estimate being -$0.09, the EPS surprise was -33.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...

Ardelyx (ARDX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.11 per share when it actually produced earnings of $0.03, delivering a surprise of 127.27%.Over the last four quarters, the compan ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________________ FORM 10-K ____________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36485 ___ ...

Investing in high-potential biotech stocks should catapult your portfolio to new heights. Picture this: a global biotech market valued at a whopping $1.55 trillion in 2023 is set to catapult to $3.08 trillion by 2030, with a compound annual growth rate of 14%. Beyond the numbers, the competitive fervor among biotechs adds an intriguing layer to this dynamic sector. In the face of such exponential growth, savvy investors have a unique opportunity to ride the wave of innovation and financial prosperity ahead. ...

Shares of Ardelyx (ARDX) have gained 6.3% over the past four weeks to close the last trading session at $9.27, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.50 indicates a potential upside of 34.8%.The average comprises seven short-term price targets ranging from a low of $11 to a high of $15, with a standard deviation of $1.55. While the lowest estimate indicates an incre ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock aliv ...

Ardelyx (ARDX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnin ...